Chief Executive Officer
CurrentIdiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology characterized by progressive fibrosis of the lungs leading to respiratory failure and death with a median survival of about 3 years consequent to diagnosis. Other lung fibrosis is a prominent feature of multiple diverse diseases, including connective tissue related interstitial lung disease, sarcoidosis, non-specific interstitial pneumonia (NSIP), drug and toxin-induced lung disease and occupational lung diseases such as silicosis. The company's research is focused on finding a potential therapy for such disease. Currently, available treatments are limited with several unwanted side effects, rendering patients with such pathologies undertreated. NOXON's is dedicated into the development of a therapeutic product for IPF using unique antioxidant platform, which was shown through many preliminary studies to be effective and has no side effects.